A clinical data-driven machine learning approach for predicting the effectiveness of piperacillin-tazobactam in treating lower respiratory tract infections.
Journal:
BMC pulmonary medicine
PMID:
40097977
Abstract
BACKGROUND: In hospitalized patients, inadequate antibiotic dosage leading to bacterial resistance and increased antimicrobial use intensity due to overexposure to antibiotics are common problems. In the present study, we constructed a machine learning model based on patients' clinical information to predict the clinical effectiveness of Piperacillin-tazobactam (TZP) (4:1) in treating bacterial lower respiratory tract infections (LRTIs), to assist clinicians in making better clinical decisions.